Event Type
Disclosure
Mandatory
Variant
8-K
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On January 7, 2026, Salarius Pharmaceuticals, Inc. (the “ Company ” or the “Registrant
and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the
. Other Events. On January 7, 2026 , the Company announced that it intends for its common stock to cease trading under the ticker symbol “SLRX” and begin tradin
.Financial Statements and Exhibits. (d) Exhibits Item 9.01.Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 3.1 Certificate of